MYOM3

Across TCGA pan-cancer cohorts, MYOM3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MYOM3 data layer compared with 25 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MYOM3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MYOM3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

LUAD, HNSC, and LSCC are the cancer types where MYOM3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.388	0.910	.036	4	view →
HNSC	DFS	Tertile	III,IV	1.000	0.911	.042	2	view →
LSCC	DFS	Median	II,III,IV	1.000	0.341	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MYOM3–LUAD (OS)

Open the LUAD breakdown →